ASCO GU Symposium 2025: Focus on Renal Cell Carcinoma
Advertisement
Dr. Daniel Joyce gives an overview of his study that examined the use of necrosis as a prognostic indicator for mRCC.
Drs. Tawagi and Armstrong recap the hottest topics in kidney cancer research from the 2025 ASCO GU Cancers Symposium.
PRO data suggest tivozanib monotherapy maintained quality of life in patients with RCC that progressed after ICI therapy.
The findings from the substudy point to durable antitumor activity for the lenvatinib + belzutifan combination.
Dr. Albiges details the final results of COSMIC-313, highlighting the effectiveness of cabo plus nivo/ipi for aRCC.
Drs. Xu and Joyce break down the evaluation of circulating KIM-1 as a prognostic and predictive biomarker in advanced RCC.
Previous data from the phase II CALYPSO study has demonstrated the efficacy of durvalumab in combination with savolitinib.
The study found no PFS benefit for tivozanib plus nivolumab in RCC post-ICI, but tivozanib maintained quality of life.
Dr. McGregor explains the safety, efficacy, and subgroup analysis from ARC-20 in patients with previously treated ccRCC.
The study found promising results with lenvatinib + belzutifan for patients with previously treated RCC.
A long-term efficacy benefit was seen with nivolumab plus cabozantinib over sunitinib, with no new safety signals.
Increased levels of circulating KIM-1 are associated with worse outcomes for patients receiving nivo/ipi or sunitinib alone.
The first-line treatment of aRCC with cabozantinib, nivolumab and ipilimumab continued to provide PFS and ORR benefits.
Drs. Karine Tawagi and Samantha Armstrong share their thoughts on COSMIC-313, CheckMate 9ER, KEYMAKER-U03, and more.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.